ArticleFrontiers in immunology2026
Soluble IL-2 receptor and memory Treg profiles differentiate early rheumatoid arthritis from undifferentiated arthritis at initial presentation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a significant global health issue. Early diagnosis remains clinically challenging, particularly in patients with inflammatory arthritis who do not yet fulfill 2010 ACR/EULAR classification criteria (undifferentiated arthritis, UA). Methods: This retrospective study enrolled 83 treatment-experienced RA (TE-RA), 49 treatment-naïve RA (TN-RA), and 51 seropositive UA patients, as well as 60 healthy controls. Peripheral lymphocyte subsets and serum cytokines were profiled using flow cytometry and bead arrays. Least absolute shrinkage and selection operator (LASSO) regression was utilized to develop an immune-based derivation-stage classifier for distinguishing TN-RA from UA, with internal validation by bootstrap resampling (B = 1000). Results: Immunophenotypic analysis identified distinct immune profiles between TN-RA and UA at initial presentation. TN-RA was characterized by IL-2 signaling exhaustion (elevated sIL-2R, decreased IL-2), systemic inflammation (elevated IL-6, IFN-γ, and TNF-α), and compensatory memory Treg expansion (increased CD45RO+ Tregs). In contrast, UA exhibited a Th17/Treg imbalance with relatively preserved Th2 and Th17 responses. An eight-feature immune signature (sIL-2R, IL-6, CD45RO+ Tregs, CD45RO+ Treg%, IFN-γ, Th17/Treg ratio, Th2, Th17%) discriminated TN-RA from UA with an optimism-corrected AUC of 0.959 (95% CI: 0.923-0.995), adjusted for age, sex, BMI, and disease duration. sIL-2R and IL-6 were the strongest contributors, consistent with their central roles in RA pathophysiology. Conclusions: In the present study, an immune-based derivation-stage classifier showed potential for distinguishing TN-RA from UA at initial presentation. The IL-2-Treg axis perturbation represents a potential pathophysiological distinction, with sIL-2R as a candidate biomarker. These findings suggest that objective immune profiling may inform clinical decision-making when conventional criteria are inconclusive.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.